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Abstract
Background: Primary pleuropulmonary and mediastinal synovial sarcomas (PPMSSs) are extremely rare. The authors
present the largest series in an Asian population.
Methods: Between 2000 and 2015, 26 genetically confirmed PPMSSs were included. The clinicopathologic features
of all of the cases were reviewed. Immunohistochemical staining was carried out using the following antibodies:
TLE1, cytokeratin (AE1/AE3), EMA, CD99, Bcl-2, CK7, CD34, S-100 protein, and Ki-67. The chromosomal translocation
t(X;18)(p11.2;q11.2) was detected by fluorescence in situ hybridization (FISH) and reverse transcription polymerase
chain reaction (RT-PCR). We compared the clinical, pathologic, immunohistochemical, and molecular features of this
series with that of the previous series and soft tissue synovial sarcomas.
Results: This series included 17 males and nine females. The median age was 36.5 years (range, 16–72 years). The
tumors involved the lung (76.9 %), pleura (15.4 %), and mediastinum (7.7 %). The median tumor size was 6 cm
(range 2.3 ~ 24 cm). The majority of the tumors were well-circumscribed. The tumors were classified as monophasic
(84.6 %), biphasic (3.8 %), and poorly differentiated (11.5 %) types. The tumors were graded as French Federation of
Cancer Centers (FNCLCC) grade 2 (62.5 %) and FNCLCC 3 (37.5 %). Diffuse immunostaining for TLE1, BCL-2, and CD99
was identified in 91.7, 95.7, and 56.0 % of the tumors, respectively. Focal positivity was seen with EMA (84.6 %), CK7 (55.
6 %), cytokeratin (AE1/AE3) (68.0 %), CD34 (5.0 %), and S-100 protein (21.7 %). A high Ki-67 index (≥10 %) was observed
in 91.3 % of the tumors. The fusion transcripts included SS18-SSX1 (15/22, 68.2 %), SS18-SSX2 including variants (6/22,
27.3 %), and SS18-SSX4 (1/22, 4.5 %) fusions. The remaining four cases showed positivity for SS18 rearrangement by
FISH. Surgical excision of tumors or lobectomy were performed in 20 patients, and seven of the patients underwent
adjuvant therapy. Clinical follow-up was available in 73.1 % cases, with a median follow-up of 12.0 months. The median
survival time was 14.5 months. Tumor resection (p = 0.024) and no residual tumor (p = 0.004) were associated with an
improved overall survival time.
Conclusions: PPMSS is a highly aggressive neoplasm. Extensive surgical resection of the tumor and more effective
adjuvant therapy should be advocated. PPMSS must be differentiated from similar diseases.
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Background
Synovial sarcoma (SS) is a morphologically, clinically, and
genetically well-defined soft-tissue neoplasm. SSs are charac-
terized by the t(X;18)(p11.2;q11.2) translocation, which leads
to SS18-SSX gene fusion [1, 2], and extremely rare neo-
plasms harbor SS18L1-SSX1, resulting from t(X;20) [3, 4].
Most tumors occur in the extremities near the joints,
followed by the trunk and head and neck regions [1, 2]. Pri-
mary SSs have also been reported to arise from a variety of
unusual locations, such as the mediastinum, retroperito-
neum, and various viscera [1, 2].
Primary pleuropulmonary and mediastinal SSs
(PPMSSs) are extremely unusual and have gradually
been recognized as a clinicopathological entity [4, 5]
since this type of peculiar tumor has been described in
the literature over the past 26 years [6]. A diagnosis of
PPMSS is difficult for clinicians and pathologists because
of the rare nature of the tumor.
To the best of our knowledge, there have been 13 series
consisting of five or more cases of PPMSSs in the English lit-
erature [7–19], and only seven of these studies were genetic-
ally confirmed. Among these t(X;18)(p11.2;q11.2)-positive
series, five of them were confirmed by reverse transcription
polymerase chain reaction (RT-PCR) [8, 12–14, 16], and the
remaining two series were confirmed by fluorescence in situ
hybridization (FISH) [15] and classical cytogenetics [11],
respectively.
To better understand the clinicopathologic spectrum
of these rare lesions, the authors describe a series of 26
genetically confirmed PPMSSs at one of the largest med-
ical centers in China. This series is the third largest in
the English literature and is the largest population-based
analysis in an Asian population.
Methods
Patients
This study was approved by the West China Hospital In-
stitutional Review Board. A SNOMED search of the hos-
pital surgical pathology files from January 2000 to May
2015 identified 489 spindle cell tumors located in the
pleuropulmonary and mediastinal area, whereas 24265
lung carcinomas were detected during this period. The
tumors were reviewed by two pathologists with soft tissue
tumor pathology expertise (H.Z. and H.C) and three gen-
eral surgical pathologists (T.L., B.X., and T.Z). Two hun-
dred and seventy-seven of the spindle cell tumors were
sarcomas. Eighty-seven metastatic sarcomas (including 28
SSs) were excluded, and 190 of 277 spindle cells sarcomas
were primary tumors. SS was the most common primary
sarcoma (28/190, 14.7 %) in this location, followed by lipo-
sarcoma (14/190, 7.4 %), Ewing sarcoma (13/190, 6.8 %),
leiomyosarcoma (13/190, 6.8 %), and chondrosarcoma
(11/190, 5.8 %). Finally, 26 t(X;18)(p11.2;q11.2) -positive
PPMSSs were included in this study.
Radiology methods
All the available images were reviewed by a radiologist
with thoracic and oncologic imaging expertise (J.Y.).
Several parameters were evaluated, including the margin,
pleural effusion, mediastinal shift, tumor heterogeneity,
enhancement, presence of calcification, necrosis/cystic
change and lymphadenopathy.
Histologic evaluation
The tumors were classified into monophasic, biphasic,
and poorly differentiated types according to the criteria
proposed by the World Health Organization [1] and
Enzinger and Weiss's Soft Tissue Tumors [2]. Grading
was performed following the French Federation of Can-
cer Centers (FNCLCC) grading system [20].
Immunohistochemistry
Immunohistochemical staining was carried out on
formalin-fixed paraffin-embedded (FFPE) tissue, using
the EnVision Plus detection system (DAKO, Carpinteria,
CA) with controls. Standard immunohistochemical stud-
ies were performed using the following antibodies:
TLE1, cytokeratin (AE1/AE3), EMA, CD99, Bcl-2, CK7,
CD34, S-100 protein, and Ki-67 (Table 1). The staining
intensity of TLE1 was graded as “3+”, “2+”, “1+” or “-”
(negative) according to Terry et al. [21]. The index of
Ki-67 ≥ 10 % was considered high [22].
When staining for TLE1, 39 nonsynovial sarcomas
were selected as the control samples, including ten soli-
tary fibrous tumors (SFTs), six spindle cell carcinomas,
ten type A thymomas, ten malignant mesotheliomas,
and three type I pleuropulmonary blastomas.
Fluorescence in situ hybridization (FISH)
All the 26 tumors had material available for FISH stud-
ies. We used a commercially available Vysis LSI SS18
Dual Color Break Apart Probe (Abbott Molecular, Des
Plaines, IL, USA) for SS18 on chromosome 18q11.2. The
first probe was labeled in spectrum orange (telomeric, 5’
to SS18, 650 Kb), whereas the second probe was labeled
in spectrum green (centromeric, 3’ to SS18, 1040 Kb).
The FISH analyses were performed according to the
manufacturer-provided protocol. FISH assays were
carried out on 4-μm-thick FFPE tissue sections. The sec-
tions were deparaffinized in xylene twice for 30 min, and
dehydrated in 100 % ethanol twice for 5 min. The sec-
tions were pretreated using the Paraffin Pretreatment
Kit (Vysis). Tissue sections were then digested with Di-
gest All-3 (Zymed, San Francisco, CA, USA) twice for
5 min. Tissue sections were denatured at 83 °C for
5 min and hybridized overnight at 42 °C in a humidified
chamber. The slides were then washed with 0.3 % NP40/
2 × SSC at 73 °C for 2 min, and again with 0.1 % NP40/
2 × SSC at room temperature for 2 min. Slides were
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counterstained with 2.0 μg/ml of 4',6-diamidino-2-phe-
nylindole (Abbott Molecular, Des Plaines, IL, USA).
Tumor samples were scored by two investigators in 100
cells in a blind fashion in each case. A split signal pat-
tern was considered positive for the gene rearrangement
if the distance between the green and the red signals
were greater than the diameter of any two signal. A case
was considered positive for rearrangement when 10 % or
more of the cells showed split apart signals.
Reverse transcription polymerase chain reaction (RT-PCR)
Using reverse transcriptase polymerase chain reaction
(RT-PCR) analysis, 23 cases with enough material were
analyzed for the presence of the fusion genes SS18-SSX1,
SS18-SSX2, and SS18-SSX4. Total RNA was isolated
from 10-μm sections of FFPE tissue material using the
High Pure FFPE RNA Micro Kit (Qiagen, Valencia, CA),
according to the manufacturer’s instructions. To elimin-
ate the contamination of genomic DNA, RNA samples
were treated with DNase I. RNA reverse-transcription
into cDNA was performed using the Transcriptor First
Strand cDNA Synthesis kit (Roche Applied Science, In-
dianapolis, IN) for 1 h at 42 °C and 5 min at 85 °C using
SSX-1/2-b reverse primer: 5’CATTTTGTGGGCCA-
GATGC3’. All polymerase chain reactions (PCRs) were
performed for 30 cycles using the GoTaq DNA polymer-
ase with GoTaq green buffer (Promega, Madison, WI)
with the following cycle conditions: denaturation at 94 °C
for 7 minute, annealing at 58 °C for 30 s, and extension at
72 °C for 30 s. The primers were used in the following
combinations: SS18-SSX consensus forward primer: 5'-
agaccaacacagcctggaccac; SS18-SSX1–specific reverse
primer: 5'-acactcccttcgaatcattttcg; SS18-SSX2–specific re-
verse primer: 5'-gcacttcctccgaatcatttc and SS18-SSX4–spe-
cific reverse primer: 5'-gcacttccttcaaaccattttct. Normal
lung tissue was used as the negative control, and
glyceraldehyde-3-phosphated ehydrogenase (GAPDH) as
the reference gene. Products of classic fusion gene were
108 bp. The PCR products were gel purified by using the
QIAquick Gel Extraction kit (Qiagen, Valencia, CA) and
sequenced by using an ABI PRISM 3100 Genetic Analyzer
(Applied Biosystems, Foster City, CA).
Statistical analysis
Summary statistics were obtained using standard
methods. Survival analyses were computed by the
Kaplan-Meier method. Gender, age at presentation
(<37 years old, ≥37 years old), tumor size (<5 cm,
≥5 cm), FNCLCC grade, mitotic rate (<10/10 high power
filed, ≥10/10 high power filed), gene fusion type (SS18-
SSX1, SS18-SSX2), tumor resection (yes, no) and residual
tumor status (yes, no; assessed microscopically) (residual
tumor was defined as treatment without tumor resection
or resected tumors with positive margins) were consid-
ered to have prognostic value, and the log-rank test was
used to compare the two aspects of the different groups.
Differences were considered statistically significant when
P < 0.05. SPSS 22.0 statistical software (IBM Corp,
Armonk, NY, USA) was used for all statistical analysis.
Results
Clinical findings
The clinical findings are summarized in Table 2. This
study included 17 males and nine females (ratios, 1.9:1.0)
aged from 16 to 72 years (median, 36.5 years; mean,
37.8 years). The most common symptoms at presentation
were cough, chest pain and dyspnea (24/26, 92.3 %), and
the remaining two patients were found incidentally. The
tumors involved the lung (20/26, 76.9 %), pleura (4/26,
15.4 %), and mediastinum (2/26, 7.7 %). The tumor size
ranged from 2.3 to 24 cm (median, 6 cm; mean, 8.5 cm).
None of the patients showed any evidence of primary ma-
lignancy elsewhere at the time of diagnosis. Smoking in-
formation was available for 18 patients, and 38.9 % (7/18)
of the patients had a history of smoking.
Surgical excision of the tumor or a lobectomy were
performed in 20 patients (76.9 %). Ten (50 %) of these
patients underwent local lymph node dissection, and
seven (35 %) received postoperative chemotherapy or
Table 1 Antibodies performed and subcellular distribution
Antibody Laboratory Clone Dilution Subcellular distribution
TLE1 Santa Cruz Biotechnology, USA polyclonal M-101 1:100 Nucleus
cytokeratin Dako, Carpintera CA monoclonal AE1/AE3 1:200 Cytoplasm/Membrane
EMA Dako, Carpintera CA monoclonal E29 1:100 Cytoplasm/Membrane
CD99 Dako, Carpintera CA monoclonal 12E7 1:100 Cytoplasm/Membrane
Bcl-2 Dako, Carpintera CA monoclonal 124 1:200 Membrane
CK7 Dako, Carpintera CA monoclonal OV-TL 12/30 1:100 Cytoplasm
CD34 Buffalo Grove, IL monoclonal QBEnd/10 1:50 Cytoplasm
S-100 protein Dako, Carpintera CA polyclonal anti-S-100 1:400 Cytoplasm
Ki-67 Dako, Carpintera CA monoclonal MIB-1 1:100 Nucleus
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1 M/48 y Cough, Dyspnea/
24 m; Chest pain/
1 m
NA 15 RLL NA NA ND Lobectomy NA NA
2 M/52 y Cough,
Expectoration, Blood
in phlegm/4 d
NA 3.5 RLL - - ND Lobectomy NA NA
3 F/27 y Cough,
Expectoration/1 m
Never 5 RLL pleura - - Lobectomy, Lymph node
dissection, Chemotherapy
(EADM + IFO + DTIC)
NA NA
4 F/42 y Chest pain,
Hemoptysis/6 m
Never 13 RMLL pleura - - Lobectomy, Lymph node
dissection
NA NA
5 M/30 y Cough, Chest pain/
15 d
10 y 24 LP ND ND ND Chemotherapy
(IFO + EADM + DDP)
NA NA
6 M/27 y Cough, Chest pain,
Dyspnea/6 m; Blood
in phlegm/1 w
Never 15 LLUL ND ND ND Biopsy only Local lymph node
metastasis/at presentation
DOD/11 m
7 F/53 y Cough, Hemoptysis/
6 m
Never 6 LUL - - - Lobectomy, Lymph node
dissection, Chemotherapy
(CTX + VCR + EADM)
Localized/45 m DOD/51 m
8 M/20 y Cough, Chest pain/
NA
NA 3 RML ND ND ND Biopsy only Intrapulmonary metastasis/at
presentation
DOD/8 m




NA NA ND Tumorectomy Localized/6 m DOD/12 m
10 F/72 y Cough,
Expectoration/3 d
NA 5 RLL pleura - NA Lobectomy, Lymph node
dissection
Intrapulmonary metastasis/29 m DOD/32 m
11 M/28 y Cough/24 m;
Hemoptysis/2 d
NA 6 LUL - - NA Lobectomy, Lymph node
dissection
NA NA
12 M/62 y Cough, Blood in
phlegm/3 m






13 F/34 y Cough,
Expectoration,
Hemoptysis/1 m
Never 3.5 LLL - - - Lobectomy, Lymph node
dissection, Chemotherapy
(IFO + EADM)
Localized/26 m; Left chest wall/
36 m;Left rib/39 m; Right lung
and spine metastasis/51 m
AWD/
52 m
14 M/26 y Cough, Chest pain,
Dyspnea/20 d
7 y 14 LUL pleura + ND Lobectomy Localized/8 m DOD/11 m
15 F/38 y Cough, Chest pain/
NA
NA 8 LUL NA NA ND Lobectomy NA NA
16 F/46 y Cough, Chest pain/
24 m
Never 2.3 RUL ND ND ND Biopsy only Brain metastasis/at presentation DOD/10 m



















18 M/46 y Cough/NA NA 4.2 LUL - - ND Lobectomy Multiple organs metastasis/2 m DOD/18 m
19 M/20 y Asymptomatic Never 3.5 RUP - - ND Tumorectomy,
Chemotherapy (IFO + DDP
+ EADM), Radiotherapy
Left lung metastasis/24 m AWD/
24 m
20 M/36 y Asymptomatic Never 4.5 LLL - - - Lobectomy, Lymph node
dissection
NO NED/4 m
21 M/16 y Cough, Hemoptysis/
NA
Never 6 RL pleura + ND Partial tumorectomy NO DOD/18 m




6 y 5 LP lung + ND Tumorectomy NO DOD/9 m
23 M/47 y Chest pain, Dyspnea/
5 m




24 M/60 y NA 30 y 7 LUL - - - Lobectomy, Lymph node
dissection, Postoperative
Localized/9 m AWD/9 m
25 M/37 y Cough,
Expectoration,Chest
pain, Dyspnea/1 m
10 y 4 LUL - - - Lobectomy, Lymph node
dissection
NO NED/1 m




myocardium - ND Tumorectomy,
Chemotherapy
Localized/2 m DOD/26 m
Abbreviation: NA not available, ND not done, “+” positive, “-” negative. W well-defined, I ill-defined, LLL left lower lobe, LUL left uper lobe, RLL right lower lobe, RUL right uper lobe, RML right middle lobe, RMLL right
middle and lower lobe, LLUL left lower and uper lobe, LP left pleura, LUP left uper pleura, RUP right uper pleura, y year, m month, w week, d day, EADM Epirubicin, IFO Ifosfamide, DTIC Dacarbazine, DDP cis-












radiotherapy. Three of the six inoperable patients were
treated with chemotherapy.
Radiologic findings
Radiology information were available for 23 patients, in-
cluding ten conventional chest radiographs, 21 com-
puted tomography (CT) images, and two magnetic
resonance imaging (MRI) studies.
On the chest radiographs, all the masses were oval or
round shaped with sharp or partly defined margins that
were homogeneous without calcification or cavities. Ipsi-
lateral pleural effusions were observed in six patients.
On CT (Fig. 1), the margins were well-defined in 14/
21 (66.7 %) tumors, ill-defined in 1/21 (4.8 %), and infil-
trative in 6/21 (28.6 %). Fifteen cases had contrast-
enhanced CT data available, and those tumors showed
heterogeneous (14/15, 93.3 %) or homogeneous en-
hancement (1/15, 6.7 %). Necrosis/cystic changes were
observed in 11/21 tumors (52.4 %), and calcification was
identified in 1/21 (4.8 %). Seven tumors (7/21, 33.3 %)
showed lymphadenopathy. Enhancing tumor vessels were
identified in two cases. A contralateral mediastinal shift
was observed in 7/21 (33.3 %) cases, and ipsilateral pleural
effusions were observed in 12/21 (57.1 %) patients.
On MRI, the T1-weighted and T2-weighted images re-
vealed lobulated lesions with sharp margins (2/2). One
tumor showed a peripheral rim enhancement after the ad-
ministration of gadopentetate dimeglumine. Cystic areas
of hyperintensity suggestive of necrosis, hemorrhage, or
myxoid material were observed in one tumor on T2-
weighted images.
Gross and histologic findings
The macroscopic descriptions were available in 18 of the
20 resected specimens. Thirteen (72.2 %) tumors were
well-circumscribed and surrounded by thin fibrous pseu-
docapsules or unencapsulated, and the remaining five
(27.8 %) tumors were poorly circumscribed. On cut sec-
tions, the tumors were white-gray to tan and soft fleshy
to rubbery in texture. Twelve tumors (66.7 %) contained
focal necrosis and hemorrhage. Cystic changes were ob-
served in four cases (22.2 %). No grossly visible calcifica-
tion was observed.
The histologic findings are summarized in Table 3.
The tumors were classified into monophasic SS (MSS)
(22/26, 84.6 %), biphasic SS (BSS) (1/26, 3.8 %), and
poorly differentiated SS (PDSS) (3/26, 11.5 %). The ma-
jority of the MSSs were composed of monomorphous
spindle-shaped cells with moderate cytoplasm and
hyperchromatic nuclei with inconspicuous, small nucle-
oli (Fig. 2a). The only case of BSS was predominantly
composed of oval epithelial nests surrounded by malig-
nant spindle cells (Fig. 2b). Among the three PDSSs, two
cases were composed entirely of high-grade spindle-
shaped cells (Fig. 2c) resembling malignant peripheral
nerve sheath tumor (MPNST), and the remaining one
tumor was predominantly composed of large epithelioid
cells (Fig. 2d) and was reminiscent of carcinoma or
Fig. 1 Primary synovial sarcoma of the lung in a 47-year-old male with chest pain and dyspnea. a Non-contrast CT (mediastinum window) scan
demonstrating a large mass of the right lung, contiguous with the right lateral pleura and the mediastinum, note the mediastinal shift. b Contrast-
enhanced CT scan (mediastinum window) showing the heterogeneous enhancement mass with predominantly cystic areas and a massive pleural
effusion (white asterisk, c). d Contrast-enhanced CT scan (lung window) revealing obvious atelectasis on the right (white asterisk)
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mesothelioma. The mitotic rate ranged from two to 36
mitoses per ten high-power field (HPF)s. Other features
included a hemangiopericytoma-like vasculature (76.9 %,
20/26), cystic changes (26.9 %, 7/26), myxoid degener-
ation (42.3 %, 11/26), necrosis (38.5 %, 10/26), and en-
trapped pneumocytes (3.8 %, 1/26) (Fig. 3a). Grading
was performed on 24 samples with sufficient material.
The tumors were classified as FNCLCC 2 (15/24,
62.5 %) and FNCLCC 3 (9/24, 37.5 %). The FNCLCC 3
tumors consisted of three PDSSs and six MSSs.
Detailed information regarding microscopic invasion
and margins was available in 17 cases. Eight tumors in-
filtrated into the adjacent tissues, and the remaining
nine were free of invasion. The surgical margins were
negative in 14 tumors and positive in three tumors. Ten
patients underwent lymph node dissections; the eight
cases with available information were free of lymph node
metastasis (Table 2).
Immunohistochemical findings
The immunohistochemical results are summarized in
Table 3. TLE1 positivity was present in 91.7 %
PPMSSs (22/24), with “≥2+” in 79.2 % (19/24) of the
tumors (Fig. 3b). In the 39 nonsynovial sarcoma sam-
ples, 94.9 % (37/39) were completely negative for
TLE1, whereas only two SFTs showed “1+” staining.
None of the control tumors showed moderate or
strong positivity (“≥2+”) for this marker. The sensitiv-
ity and specificity of TLE1 for PPMSS was 91.7 %
and 94.9 %, respectively.
Diffuse staining for Bcl-2 and CD99 was present in
95.7 % (22/23) and 56.0 % (14/25) of PPMSSs, respect-
ively. Focal positivity was seen with EMA (84.6 %, 22/
26), CK7(55.6 %, 10/18), cytokeratin (AE1/AE3) (68.0 %,
17/25), CD34 (5.0 %,1/20) and S-100 protein (21.7 %, 5/
23). A high Ki-67 index (≥10 %) was observed in 91.3 %
(21/23) of the tumors.
Table 3 Histopathologic and immunohistochemical features of 26 PPMSSs
Case NO. Subtype Grade (FNCLCC) Mitotic Rate (/10HPF) TLE1 ki-67 EMA CD99 CK7 Bcl2 cytokeratin CD34 S-100
1 MFSS 2 7 - 50 % - - - + + - -
2 MFSS 3 36 2+ 35 % + + + + + ND -
3 MFSS 2 2 3+ 6 % + - + + + ND -
4 PDSS 3 12 2+ ND + + - + + - +
5 MFSS NA 2/3HPF 2+ ND + + ND ND + - -
6 MFSS 3 12 3+ 4 % + - - + + ND -
7 MFSS 2 14 2+ 35 % + + + + + - +
8 MFSS 2 2 3+ 10 % + - - + + - -
9 MFSS 3 2 1+ 10 % + - + + - + -
10 MFSS 2 9 - ND + + - + - - -
11 MFSS 2 8 2+ 25 % + - + + - ND +
12 MFSS 2 6 ND 30 % + + ND - + - -
13 MFSS 2 4 1+ 20 % + + + + - - ND
14 MFSS 2 5 2+ 25 % + + + + + - -
15 MFSS 2 4 2+ 60 % + - + + + - ND
16 MFSS NA 2/8HPF 3+ 40 % + + + + - - -
17 PDSS 3 21 3+ 40 % + + - + - - -
18 MFSS 2 17 1+ 30 % + - ND ND + - -
19 MFSS 3 12 3+ 75 % + + - + - - -
20 MFSS 2 8 3+ 20 % - + - + + - +
21 MFSS 2 6 2+ 35 % - ND ND + ND - -
22 MFSS 3 21 3+ 45 % + - ND ND + - -
23 MFSS 2 2 2+ 45 % + - ND + + - -
24 MFSS 3 11 3+ 55 % - - ND + - - -
25 BSS 2 4 3+ 20 % + + + + + ND ND
26 PDSS 3 21 ND 20 % + + ND + + ND +
Abbreviation: NA not available, ND not done, MFSS monophasic fibrous synovial sarcoma, BSS biphasic synovial sarcoma, PDSS poorly differentiated synovial
sarcoma, HPF high power field, “+” positive, “-” negative
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FISH and RT-PCR
The molecular results are described in Table 4. By FISH,
25 cases showed SS18 rearrangement (Fig. 3c). In one of
the FISH-positive cases (case 9), at least 60 % of the nu-
clei contained two paired signals with multiple extra red
signals, and loss of green signal (Fig. 3d). One case failed
FISH based on absent fluorescent signals; this case (case 2)
showed a SS18-SSX1 fusion on RT-PCR.
Of the 23 cases subjected to RT-PCR, 22 were positive
for SS18-SSX gene fusion, whereas the remaining one
Fig. 2 Microscopic features. a Monophasic synovial sarcoma, tumor consisting of uniform hyperchromatic spindled cells arranged in a prominent
fascicular pattern (H&E, ×200). b Biphasic synovial sarcoma, composed of oval epithelial nests and surrounded by spindle cell components (H&E, ×200).
c Poorly differentiated synovial sarcoma, showing high-grade spindle-shaped cells and a hemangiopericytoma-like vascular pattern, reminiscent of a
malignant peripheral nerve sheath tumor (H&E, ×200). d Poorly differentiated synovial sarcoma, consisting of large epithelioid cells, indistinguishable
from a poorly differentiated carcinoma or mesothelioma (H&E, ×400)
Fig. 3 a Entrapped pneumocytes. The entrapped lung tissue could be observed in the peripheral areas of the monophasic synovial sarcoma, resembling
a biphasic synovial sarcoma. The entrapped pneumocytes are positive for thyroid transcription factor 1 (TTF-1) (a inset, 400×). b Tumor cells with “3+”
positively nuclear TLE1 expression (×200). c FISH demonstrating a balanced rearrangement of the SS18 locus observed in the majority of the neoplastic
cells (×1000). d In Case 9, the majority of tumor cells show two paired signals and one or multiple extra red signals, loss of green signal (arrow) (×1000)
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was negative (case 17, positive by FISH). The fusion
transcripts included SS18-SSX1 (15/22, 68.2 %), SS18-
SSX2 (6/22, 27.3 %), and SS18-SSX4 (1/22, 4.5 %) fu-
sions. DNA sequencing showed that the fusion sites of
all SS18-SSX1 and the four classical SS18-SSX2 tumors
were involved in exon 10 of the SS18 gene (codon 410)
and exon 6 of the SSX1 or SSX2 genes (codon 111),
which is typical of the ordinary fusion site of synovial
sarcoma [23]. The remaining two SS18-SSX2 tumors
(cases 18 and 20) showed involvement of exon 9 of the
SS18 gene (codon 366) and exon 5 of the SSX2 gene
(codon 94) (Fig. 4a and b), which has not been described
in the literatures. SS18-SSX4 is shown in the gel-
electrophoresis (Fig. 4c), whereas the lanes of SS18-SSX1
and SS18-SSX2 were clear. However, sequencing of this
rare sample failed.
Survival analysis
Relapse and survival information are summarized in
Table 2. Follow-up data were available for 73.1 % of cases
(19/26) with a median follow-up time of 12.0 months;
these data included 15 patients with localized disease and
four patients with tumor metastasis at presentation.
Among the 15 patients with localized disease, ten (66.7 %)
suffered disease progression two to 51 months after diag-
nosis (median, 8.5 months; mean, 15.9 months), including
six patients with local recurrence and five patients with
metastasis. Thirteen patients (68.4 %) died of the disease
within 51 months. Four patients (21.1 %) were alive with
the disease. Two (10.5 %) were disease free with a short
follow-up time. No patients lived without evidence of dis-
ease for more than 24 months. In the entire cohort, the
median survival time (MST) was 14.5 months (range 1–52
months). The 2-year disease-specific survival was 27.7 %.
Log-rank analyses on the prognostic parameters were
as follows: gender (χ2 = 1.25, p = 0.246 > 0.05), age (≥37
vs. <37; χ2 = 0.064, p = 0.800 > 0.05), tumor size (≥5 cm
vs. <5 cm; χ2 = 0.56, p = 0.454 > 0.05), FNCLCC grade
(χ2 = 0.17, p = 0.685 > 0.05), fusion gene types (SS18-SSX1
vs. SS18-SSX2; χ2 = 0.10, p = 0.756 > 0.05), mitotic rate
Table 4 FISH and RT-PCR features of 26 PPMSSs
Case NO. FISH RT-PCR Fusion site of exon Fusion site of codon
1 + SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
2 failed SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
3 + SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
4 + SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
5 + ND ND ND
6 + SS18-SSX2 SS18:exon 10 SSX2:exon 6 SS18:codon 410 SSX2:codon 111
7 + SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
8 + SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
9 + SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
10 + ND ND ND
11 + SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
12 + SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
13 + SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
14 + SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
15 + SS18-SSX2 SS18:exon 10 SSX2:exon 6 SS18:codon 410 SSX2:codon 111
16 + SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
17 + - - -
18 + SS18-SSX2, variant SS18:exon 9 SSX2:exon 5 SS18:codon 366 SSX2:codon 94
19 + SS18-SSX2 SS18:exon 10 SSX2:exon 6 SS18:codon 410 SSX2:codon 111
20 + SS18-SSX2, variant SS18:exon 9 SSX2:exon 5 SS18:codon 366 SSX2:codon 94
21 + SS18-SSX2 SS18:exon 10 SSX2:exon 6 SS18:codon 410 SSX2:codon 111
22 + SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
23 + ND ND ND
24 + SS18-SSX4 failed failed
25 + SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
26 + SS18-SSX1 SS18:exon 10 SSX1:exon 6 SS18:codon 410 SSX1:codon 111
ND not done, “+” positive, “-” negative
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(≥10/10 HPFs vs. <10/10 HPFs; χ2 = 0.01, p = 0.925 > 0.05),
tumor resection (yes vs. no; χ2 = 5.13, p = 0.024 < 0.05)
and tumor residual status (yes vs. no; χ2 = 8.55, p =
0.004 < 0.05). Surgical resection and no residual tumor
were associated with significantly improved overall
survival (OS). No significant difference was observed
between two sides of the other survival factors.
Discussion
PPMSSs are extremely rare; however, according to our
series, SS accounted for 14.7 % of all primary sarcoma in
pleuropulmonary and mediastinal area and seems to be
the most common primary sarcoma type in this region.
A preference for location at the lung (76.9 %) was ob-
served, which was similar to the findings of prior studies
[11, 14, 15]. Additionally, lung appears to be the most
common organ-based location for SS [24]. Therefore,
more attention should be paid to this peculiar entity.
In this study, the tumors displayed a male predomin-
ance (17 males and nine females; ratio, 1.9:1.0), which is in
agreement with a previous series (ratio, 2.0:1.0) [9]. In
contrast, a study from Japan showed a female dominance
(ratio, 0.6:1.0) [12]. However, there was no obvious sex
predominance in the majority of previous studies [10, 11,
13–17]. Our findings demonstrated that PPMSSs often de-
velop in young to middle-aged adults (median, 36.5 years;
mean, 37.8 years), older than that of the soft tissue coun-
terpart (median, 34.0 years [25]). Historical series showed
similar findings. Chan et al. [26] observed that SS in older
people were more likely to occur in unusual regions. The
mean age of patients with PPMSS in this study was some-
what lower than that reported in the largest series [14]
(37.8 years vs. 42 years) and much lower than that of the
Japanese series [12] (37.8 years vs. 58 years). Cough, chest
pain and dyspnea were the common presenting signs and
symptoms in this study, whereas a few cases were detected
incidentally. In our study, only a single patient developed
pneumothorax; however, in the series of Cummings et al.
[27], pneumothorax appeared to be a frequent event in
cystic pulmonary SSs, partly because of the superficial lo-
cation of the masses.
Radiographically, PPMSSs are typically homogenous
and well-defined, and ipsilateral pleural effusions could
be observed in most cases. On CT, the tumors in this
Fig. 4 RT-PCR for SS18-SSX gene fusions. Rare fusion site for SS18-SSX2 fusion transcript (case 18) (a and b). a Gel electrophoresis of the RT-PCR product.
Lane M, size marker; Lane 1, positive control; Lane 2, negative control; Lane 3, blank control; Lane 4, internal control (GAPDH); Lane 5, SS18-SSX1; Lane
6, SS18-SSX2; Lane 7, SS18-SSX4. b Partial nucleotide sequence of the SS18-SSX2 fusion transcript; the fusion sites (arrow) are involved in exon 9 of the
SS18 gene (codon 366) and exon 5 of the SSX2 gene (codon 94). c SS18-SSX4 (case 24). The gel-electrophoresis demonstrates obvious SS18-SSX4, with
clean lanes of SS18-SSX1 and SS18-SSX2
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study could present with sharp (66.7 %) or ill-defined
(33.3 %) margins. The tumors were manifested by het-
erogeneous enhancement and rarely by homogeneous
enhancement, which was similar to the findings of earl-
ier studies [16–19] and their soft tissue counterparts
[28]. Calcification was absent in our series and in most
previous series although it is a common feature of soft
tissue SSs [28]. A mediastinal shift was usually observed
in the patients with very large masses, and ipsilateral
pleural effusions are also a common sign. Generally, the
“triple signal” pattern (hypointense, isointense, and hy-
perintense) was a frequent event on T2-weighted mag-
netic resonance imaging [17].
Grossly, the majority of tumors (72.2 %) in this study
were well circumscribed, and the tumors exhibited a variety
of hemorrhage, necrosis, and cystic changes, which were
similar to those seen in previous reported SSs [14, 17].
Histologically, MSS (84.6 %) was the main subtype,
followed by PDSS (11.5 %) and BSS (3.8 %); these features
are similar to the prior PPMSS series [11–16] and soft
series [25, 28]. In this series, microscopic calcification was
absent, and some previous series also showed that calcifi-
cation appears to be much less common than in soft tissue
lesions (15 % vs. 30 %) [9, 11, 13, 14, 28].
The proportions of FNCLCC 2 (62.5 %)) and FNCLCC
3 (37.5 %) in our series were similar to the largest series
(75.8 % and 24.2 %, respectively) [14] and most soft tis-
sue SSs (69.0 ~ 74.0 % and 26.0 ~ 31.0 %, respectively)
[29, 30]. However, the proportion of FNCLCC 3 in
Begueret’s study [13] was as high as 70 %. The explan-
ation for the difference between the results of Begueret
et al. [13] and other authors requires further studies.
TLE1 has recently emerged as a new marker for the
diagnosis of SS [15, 21]. However, the diagnostic value of
this antibody remains controversial [31]. In this series,
TLE1 demonstrated high sensitivity (91.7 %) and specifi-
city (94.9 %) for PPMSSs. Although some SFTs showed
weak positivity for TLE1, none of the nonsynovial sarco-
mas were moderately or strongly reactive for this marker.
Therefore, TLE1 could be used as a screening marker
prior to the detection of t(X;18)(p11.2;q11.2) [32].
A high Ki-67 index (≥10 %) in our study occurred in
91.3 %, which was higher than in the prior Japanese
series [12] (45.5 %) and in most soft tissue counterparts
[22] (26.5 ~ 86.0 %). Ki-67 has been suggested as a prog-
nostic factor in synovial sarcoma [22], and the poor
prognosis might be partly explained by this high Ki-67
staining in our series.
In this series, the fusion transcripts included SS18-SSX1
(68.2 %), SS18-SSX2 (27.3 %), and SS18-SSX4 (4.5 %)
fusions, and the proportion of SS18-SSX1 and SS18-SSX2
fusions were similar to that in previous studies [12–14].
However, some different findings were as follows. First, we
found a single case harboring a SS18-SSX4 fusion
transcript. This fusion presents in only 1–2 % of SSs [25],
and to the best of our knowledge, this extremely rare fusion
has not been previously reported in PPMSS before. This
case was classified as MSS (FNCLCC 3). Local recurrence
occurred 9 months after the tumor excision and postopera-
tive radiotherapy. Second, two cases harboring rare fusion
site of SS18-SSX2 fusion transcript were identified and this
fusion site has not been previously reported in SSs. Further
studies are needed to determine whether the variant fusion
site is specific to PPMSS. Third, one case was found to har-
bor a complex pattern by FISH analysis. This case exhibited
two paired signals with multiple extra red signals and loss
of green signal, which are suggestive of a cryptic rearrange-
ment of the 5’ region of the SS18 gene; this case was proven
to be SS18-SSX1 by subsequent RT-PCR. This finding has
not been described in PPMSSs, although it has been re-
ported in soft tissue SSs [33, 34], and the presence of aneu-
ploidy or amplificon of chromosome 18q might account for
this event. This case was MSS (FNCLCC 3) and was the
only case with massive necrosis in our series. This patient
developed a local recurrence only 6 months after the tumor
excision and died 12 months after diagnosis. However,
more samples are needed to further analyze the correlation
of prognosis and the special genetic changes.
The differential diagnosis of PPMSS is broad and
might be very challenging, especially in small biopsy
samples. This neoplasm must be differentiated from sec-
ondary SS and other primary spindle cell neoplasms in
these locations.
The intrathoracic area is an extraordinarily rare loca-
tion for SS. For example, in our Medical Centre, among
the 56 cases of SS in this location, 50 % were metastatic
tumors. Therefore, the possibility of a secondary SS
should always be excluded. In this series, detail clinical
information ruled out the possibility of metastatic le-
sions arising from other sites.
Sarcomatoid carcinoma could have a conspicuous
spindle cell component and show focal positivity for
only epithelial markers, simulating SS. SS could also dis-
play epithelioid features and might be confused with
carcinomas or mesothelioma. Therefore, sarcomatoid
carcinoma and mesothelioma should always be the pri-
mary consideration in the differential diagnosis of SS.
However, carcinoma and mesothelioma could be distin-
guished from SS in several aspects. First, the radiologic
findings usually show an infiltrative border for
carcinoma and a diffuse growth pattern for mesotheli-
oma, whereas PPMSS typically appears as a well-
circumscribed mass with uniform opacity [17]. Second,
sarcomatoid carcinoma and mesothelioma are usually
more pleomorphic than SS, and extensive sampling of
the lesion could help identify an underlying histologic
subtype of lung carcinoma. Third, neither sarcomatoid
carcinoma nor mesothelioma exhibit strong reactivity
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for TLE1 in this study and Lino-Silva et al. [15] although
Matsuyama et al. [35] found TLE1 staining in 69 % of me-
sotheliomas. Fourth, identification of t(X;18)(p11.2;q11.2)
could be invaluable for extremely challenging cases.
Type A thymomas and type I pleuropulmonary blasto-
mas could share clinical and morphological features with
PPMSS. However, type I pleuropulmonary blastomas
typically develop in infants and during early childhood.
In contrast, PPMSSs typically occur in older patients
[13, 14]. Careful morphologic inspection and ancillary
immunohistochemical stains and molecular studies are
helpful in distinguishing between these lesions.
Intrathoracic SFTs might share some morphologic fea-
tures with PPMSSs. SSs always do not exhibit diffuse re-
activity for CD34 [2], whereas SFT usually do not show
strong positivity for TLE1, as seen in the this study. SFTs
are negative for t(X;18)(p11.2;q11.2) and have been shown
to harbor a characteristic NAB2-STAT6 fusion gene [36].
Very recently, STAT6 has proven to be a highly sensitive
and specific marker for the diagnosis of SFT [37].
MPNST could closely resembles SS and appears to be
the most challenging tumor type in the differential diag-
nosis of SS in any location. A full panel of markers in-
cluding TLE1 and molecular genetic testing for
t(X;18)(p11.2;q11.2) could be useful for distinguishing
between the two tumors.
Poorly differentiated SS might be almost entirely
poorly differentiated with uniform small round cell
morphology, resembling Ewing sarcoma. Extensive sam-
pling and careful inspection are required to identify any
accompanying more typical areas of synovial sarcoma,
which play an important role in establishing the diagno-
sis. Immunostaining for TLE1 and identification of
SS18-SSX fusion instead of EWSR1-FLI-1/EWSR1-ERG
[38] could help to confirm the diagnosis.
The preferred treatment of SSs is radical resection
combined with radiotherapy and or chemotherapy,
which could remarkably or partly decrease the recurrent
or metastatic rate [39, 40]. In our series, 20 patients
(76.9 %) underwent lobectomy or tumor resection, and
82.4 % of these patients obtained negative margins.
Seven of these surgical patients (35 %) underwent adju-
vant radiotherapy or/and chemotherapy. Several previ-
ous PPMSSs series have described the treatment for
PPMSS [9–13, 16]; however, few previous studies ana-
lyzed the correlation between treatment and survival.
Our results indicated that effective excision of the tu-
mors with negative margins could significantly improve
survival (p = 0.004), and tumor resection is important
when available (p = 0.024).
According to the current study, PPMSSs appear to be
more aggressive than the soft tissue counterparts (MST,
14.5 months vs. 52 months [41]); these results are simi-
lar to the results of previous studies. The prognosis of
PPMSSs in this study appear more unfavorable than in prior
series of PPMSSs (MST, 14.5 months vs. 30 ~ 50 months)
[11–13, 15, 16]. None of the subjects in our series survived
for more than 5 years, and none of the subjects lived with
no evidence of disease for more than 2 years; the 5-year sur-
vival rate in prior series was approximately 30 % [13], and it
could reach 50 % in soft tissue SSs [11, 42]. The dismal
prognosis of PPMSSs might partly be due to later presenta-
tion and difficulties in obtaining negative surgical margins.
In terms of prognostic factors, age (better in young pa-
tients), tumor size (<5 cm), mitotic rate (<10/10HPF),
FNCLCC (low grade), status of the surgical margins
(negative), and SS18-SSX type (SS18-SSX2) were re-
ported to be associated with better survival in soft tissue
SSs [25, 30]. We found tumor resection (p = 0.024) and
no residual tumor (p = 0.004) were significantly associ-
ated with better survival. The other factors had no effect
on survival.
Conclusions
Here, we present the clinicopathological and molecular
features of 26 t(X;18)(p11.2;q11.2)-positive PPMSSs. These
tumors seem to be more aggressive than the soft tissue
counterparts and more aggressive than prior PPMSSs
series. Extensive surgical resection of the tumor and more
effective adjuvant therapy should be advocated. The diag-
nosis of PPMSS might be challenging. A combination of
clinical studies, careful morphologic analysis, and a full
panel of immunomarkers including TLE1 and genetic
studies is helpful in confirming the diagnosis.
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